Company intelligence / Profile preview

Aspireo Pharmaceuticals Ltd.

Ownership: Private
Development stage: Phase 2

Overview

Aspireo Pharmaceuticals conducted multiple clinical trials for DG3173, a novel somatostatin analog. The company completed Phase 1 and Phase 2 trials evaluating the effect of DG3173 on growth hormone levels in untreated acromegalic patients, comparing it with octreotide.

Therapeutic areas: Endocrinology
Modalities: Somatostatin analog (SSA)
Industry: Biotech

Drug pipeline

1 asset

Somatoprim

Phase 2

Indications: Acromegaly, Neuroendocrine tumors, Gastroenteropancreatic tumors, Cushing disease, Diabetic retinopathy

Partnerships

Strongbridge Biopharma Plc

Beyond the preview

Go deeper on Aspireo Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspireo Pharmaceuticals Ltd..

Explore the full profile